Ameritas Investment Partners’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-5,840
| Closed | -$277K | – | 3130 |
|
|
2025
Q3 | $277K | Sell |
5,840
-1,296
| -18% | -$62.8K | 0.01% | 1060 |
|
|
2025
Q2 | $381K | Sell |
7,136
-406
| -5% | -$18.4K | 0.01% | 952 |
|
|
2025
Q1 | $305K | Buy |
7,542
+450
| +6% | +$19.1K | 0.01% | 1036 |
|
|
2024
Q4 | $197K | Buy |
7,092
+450
| +7% | +$13.6K | 0.01% | 1330 |
|
|
2024
Q3 | $191K | Hold |
6,642
| – | – | 0.01% | 1358 |
|
|
2024
Q2 | $156K | Buy |
6,642
+467
| +8% | +$9.99K | 0.01% | 1436 |
|
|
2024
Q1 | $156K | Buy |
6,175
+1,030
| +20% | +$24.7K | 0.01% | 1465 |
|
|
2023
Q4 | $120K | Hold |
5,145
| – | – | ﹤0.01% | 1613 |
|
|
2023
Q3 | $260K | Buy |
5,145
+1,435
| +39% | +$66.8K | 0.01% | 1024 |
|
|
2023
Q2 | $173K | Buy |
3,710
+920
| +33% | +$42.2K | 0.01% | 1228 |
|
|
2023
Q1 | $107K | Hold |
2,790
| – | – | ﹤0.01% | 1495 |
|
|
2022
Q4 | $131K | Buy |
2,790
+774
| +38% | +$33.2K | 0.01% | 1397 |
|
|
2022
Q3 | $68K | Hold |
2,016
| – | – | ﹤0.01% | 1753 |
|
|
2022
Q2 | $19K | Hold |
2,016
| – | – | ﹤0.01% | 2555 |
|
|
2022
Q1 | $29K | Hold |
2,016
| – | – | ﹤0.01% | 2379 |
|
|
2021
Q4 | $43K | Hold |
2,016
| – | – | ﹤0.01% | 2211 |
|
|
2021
Q3 | $45K | Hold |
2,016
| – | – | ﹤0.01% | 2228 |
|
|
2021
Q2 | $50K | Buy |
2,016
+1,046
| +108% | +$29.4K | ﹤0.01% | 2175 |
|
|
2021
Q1 | $28K | Hold |
970
| – | – | ﹤0.01% | 2400 |
|
|
2020
Q4 | $25K | Hold |
970
| – | – | ﹤0.01% | 2348 |
|
|
2020
Q3 | $30K | Buy |
970
+240
| +33% | +$8.39K | ﹤0.01% | 2154 |
|
|
2020
Q2 | $18K | Buy |
730
+330
| +83% | +$7.54K | ﹤0.01% | 2383 |
|
|
2020
Q1 | $8K | Hold |
400
| – | – | ﹤0.01% | 2628 |
|
|
2019
Q4 | $9K | Hold |
400
| – | – | ﹤0.01% | 2761 |
|
|
2019
Q3 | $9K | Buy |
+400
| New | +$9.31K | ﹤0.01% | 2776 |
|
Other funds holding AKRO
Ameritas Investment Partners's AKRO Position: Q4 2025 in Review
Ameritas Investment Partners sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 5,840 shares — an estimated $277K sold.
Ameritas Investment Partners first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $381K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Ameritas Investment Partners reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Ameritas Investment Partners sold 5,840 Akero Therapeutics shares in Q4 2025, an estimated $277K.
- Ameritas Investment Partners first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- Ameritas Investment Partners's Akero Therapeutics position peaked at $381K in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Ameritas Investment Partners's 13F filing for Q4 2025, filed 11 Feb 2026.